Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million

2026-02-17 15:48:00 ET

On February 17, 2026, Rock Springs Capital Management disclosed in a U.S. Securities and Exchange Commission (SEC) filing that it sold 159,278 shares of Cogent Biosciences (NASDAQ:COGT) , an estimated $4.48 million trade based on quarterly average pricing.

According to its SEC filing dated February 17, 2026, Rock Springs Capital Management LP reduced its stake in Cogent Biosciences by 159,278 shares during the fourth quarter. The estimated transaction value was $4.48 million, calculated from the period’s average unadjusted closing price. The quarter-end position value increased by $15.68 million, a figure that reflects both share count changes and market price appreciation.

Cogent Biosciences, Inc. is a biotechnology company specializing in precision therapies for genetically driven diseases, with a primary focus on rare oncology indications. The company's strategy centers on advancing selective tyrosine kinase inhibitors, leveraging proprietary research and strategic partnerships to address critical gaps in treatment. Cogent's competitive edge lies in its targeted approach to drug development for underserved patient populations.

Continue reading